Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242015164 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Tiina Vesterinen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, HUSLAB, HUS Diagnostic Center, Helsinki University Hospital, University of Helsinki, 00290 Helsinki, Finland. Hauptthemen laut MEDLINE: Insulinoma, Pancreatic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Finnish Cancer Foundation, the Helsinki University Hospital Research Fund, the Hospital District of South Ostrobothnia.
Abstract (Originalsprache)
Insulinomas are rare functional pancreatic neuroendocrine tumours, which metastasize in 10% of cases. As predicting the prognosis can be challenging, there is a need for the determination of clinicopathological factors associated with metastatic potential. The aim of this study is to evaluate the glucagon-like peptide-1 receptor (GLP-1R) expression in insulinomas and to analyse its association with clinicopathological features and patient outcome. This retrospective study involves pancreatic tumour tissue samples from fifty-two insulinoma patients. After histological re-evaluation, formalin-fixed paraffin-embedded tissue samples were processed into tissue microarrays and stained immunohistochemically with a monoclonal GLP-1R antibody. Forty-eight of the forty-nine (98%) non-metastatic tumours expressed GLP-1R, while one non-metastatic, multiple endocrine neoplasia type 1 (MEN1)-related tumour and all three of the metastatic tumours lacked GLP-1R expression. The lack of GLP-1R expression was associated with impaired overall survival, larger tumour diameter, higher Ki-67 PI and weaker insulin staining. Somatostatin receptor 1–5 expression did not differ between GLP-1R-positive and GLP-1R-negative insulinomas. In conclusion, the lack of GLP-1R expression is associated with metastatic disease and impaired survival in insulinoma patients. Thus, GLP-1R expression could be a useful biomarker in estimating the metastatic potential of the tumour and the prognosis of surgically treated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, HUSLAB, HUS Diagnostic Center, Helsinki University Hospital, University of Helsinki, 00290 Helsinki, Finland.
- Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, 00290 Helsinki, Finland.
- Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.
- Department of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland.
- Endocrinology, Department of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland.
- Faculty of Social Sciences, Tampere University, 33014 Tampere, Finland.
ORCID-Profile: Tiina Vesterinen, Elina Peltola, Päivi Hannula, Heini Huhtala, Pia Jaatinen
Förderung
- the Finnish Cancer Foundation
- the Helsinki University Hospital Research Fund
- the Hospital District of South Ostrobothnia
- Research Funding provided by Tampere University and the University Consortium of Seinäjoki
- Research Funding provided by Tampere University Hospital
- Finnish Cancer Foundation
- Helsinki University Hospital Research Fund
- Hospital District of South Ostrobothnia
Zitieren
APA
Vesterinen, T., Peltola, E., Leijon, H., Hannula, P., Huhtala, H., Mäkinen, M. J., Nieminen, L., Pirinen, E., Rönty, M., Söderström, M., Jaatinen, P., & Arola, J. (2023). Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242015164
Vancouver
Vesterinen T, Peltola E, Leijon H, Hannula P, Huhtala H, Mäkinen MJ, et al. Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242015164
BibTeX
@article{Vesterinen2023,
author = {Vesterinen, Tiina and Peltola, Elina and Leijon, Helena and Hannula, Päivi and Huhtala, Heini and Mäkinen, Markus J and Nieminen, Lasse and Pirinen, Elina and Rönty, Mikko and Söderström, Mirva and Jaatinen, Pia and Arola, Johanna},
title = {Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242015164}
}
EUVIMED